Although it has been hypothesized that AR-positive ovarian tumors may also preferentially respond to treatment with AR antagonists, it remains to be determined whether AR status could serve as a reliable prognostic biomarker in this disease model. The gene discussed is AR; the disease is ovarian neoplasm.